A Northwestern Medicine-led study published in the Journal of Clinical Investigation has uncovered why older individuals with ...
Researchers in Class of 1942 Professor of Chemistry Matthew D. Shoulders' lab have uncovered a sinister hidden mechanism that ...
The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...
“Our results provide unique insights into the mechanism of action of PG3 as a novel cancer therapeutic targeting p53 pathway-like tumor suppression” As highlighted in the abstract of this study, ...
Allo-HCT outcomes for TP53-mutated AML are similar across haploidentical, matched sibling, and matched unrelated donors. The study analyzed 451 patients, showing comparable 2-year overall survival and ...
The GOG 3026 trial demonstrated that ribociclib and letrozole combination therapy achieved a 31% response rate and 84% ...
CAMBRIDGE, MA. & ROCKVILLE, MD.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), today ...
Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on ...
Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results